← Back to patent-cliff list
Baxdrostat/dapagliflozin (AstraZeneca)
Tier C — Watch / tradeBaxdrostat/dapagliflozin (AstraZeneca)
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP11B2, SGLT2
Indications (approved)：Heart failure, Hypertension, Chronic renal impairment
Regional status
US
Phase III
2024-03-29
EU
Phase III
2024-03-29
China
Phase III
2024-06-18
Japan
Phase III
2024-05-31
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Baxdrostat/dapagliflozin (AstraZeneca)?
Approved indications include: Heart failure, Hypertension, Chronic renal impairment.
When does the Baxdrostat/dapagliflozin (AstraZeneca) patent expire?
No public expiry year is available for Baxdrostat/dapagliflozin (AstraZeneca) yet; this page updates once verified.
How do I get a quote for Baxdrostat/dapagliflozin (AstraZeneca) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01